Market Cap (In USD)
8.61 Million
Revenue (In USD)
6.03 Million
Net Income (In USD)
-16.17 Million
Avg. Volume
23.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.19-5.231378
- PE
- -
- EPS
- -
- Beta Value
- 0.913
- ISIN
- DE000A1X3W00
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Selwyn Ho MB BS, MBBS
- Employee Count
- -
- Website
- https://www.medigene.com
- Ipo Date
- 2013-06-17
- Details
- Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.
More Stocks
-
1808
-
NBNKFNordea Bank Abp
NBNKF
-
FNDMFund.com Inc.
FNDM
-
ALAR
-
PHARPharos Energy plc
PHAR
-
GUREGulf Resources, Inc.
GURE
-
0086
-
REOSReoStar Energy Corp.
REOS